You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Fulgent raised its ending cash forecast to approximately $630 million and improved its full year 2026 non-GAAP loss outlook to $1.65 to $1.75 per share from $2.22 to $2.35.
Fulgent Genetics reported revenue of $90.4 million for the three months ended September 30, 2026, up 8%, while gross profit fell $3.6 million, or 10%, as billing transition delays and lower collections pressured margin.
Fulgent Genetics reported revenue of $90.4 million for the third quarter ended September 30, 2026, up approximately 8% year-over-year, and a GAAP loss of $13.2 million. It maintained 2026 revenue guidance of $330.0-$340.0 million.
Useful current figures from the complete screener profile.
* Q4 derived as the full year minus Q1 to Q3.
TL;DR. Q3 revenue grew approximately 8% year over year, revenue guidance was reaffirmed, sequential gross margins and adjusted EBITDA improved, and operating-margin, loss-per-share, and ending-cash guidance improved while AI and the therapeutic pipeline advanced. However, gross margins remained below the prior year, operating margins and earnings were still negative, the billing transition continued to weigh on results, and precision diagnostics revenue declined year over year.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Illustrative technical + ownership context — a signal mix, not investment advice.
| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA loss non-GAAP | $17.1M | Q2 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
FLGT
this stock
Fulgent Genetics, Inc.
|
$688.98M | -6.1% | +2.5% | — | 7.2% |
|
TMO
Thermo Fisher Scientific Inc.
|
$259.44B | +20.8% | +14.5% | 36.9 | 1.3% |
|
DHR
Danaher Corp
|
$163.94B | +1.8% | +8.5% | 38.1 | 1.2% |
|
IDXX
Idexx Laboratories Inc
|
$55.48B | +4.1% | +10.4% | 47.5 | 3.0% |
|
A
Agilent Technologies, Inc.
|
$49.04B | +27.8% | +6.4% | 34.2 | 1.7% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
Fulgent Genetics reported revenue of $90.4 million for the three months ended September 30, 2026, up 8%, while gross profit fell $3.6 million, or 10%, as billing transition delays and lower collections pressured margin.
View| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| FLGT | +3.9% | +24.5% | +39.6% | +19.6% | -6.1% |
| SPY | +2.6% | -1.2% | +0.5% | -0.2% | +10.6% |
| vs SPY | +1.3% | +25.6% | +39.1% | +19.8% | -16.8% |
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.
